NCT00175825

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.

Conditions

• Epilepsy

Interventions

Type	Name	Description
OTHER	Placebo	Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
DRUG	Brivaracetam	Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period

Timeline

• Start date: 2005-11-07
• Primary completion: 2006-06-29
• Completion: 2006-06-29
• First posted: 2005-09-15
• Last updated: 2018-10-02
• Results posted: 2018-08-22

Locations

42 sites across 4 countries: United States, Brazil, India, Mexico